<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Nicardipine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00622</strong>&#160; (APRD00088)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00622/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00622/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00622.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00622.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00622.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00622.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00622.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00622">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Nicardipino</td><td>Spanish</td><td>INN</td></tr><tr><td>Nicardipinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Nicardipine Hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000499/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000499/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: AIKVCUNQWYTVTO-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 515.182313414</li>
              <li>Average Mass: 515.986</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000499">DBSALT000499</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cardene</td><td>Roche</td></tr><tr><td>Cardene IV</td><td>ESP Pharma</td></tr><tr><td>Cardene SR</td><td>Roche</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li>
<li><a href="/mesh/anti-arrhythmia-agents">Anti-Arrhythmia Agents</a></li>
<li><a href="/mesh/vasodilator-agents">Vasodilator Agents</a></li>
<li><a href="/mesh/calcium-channel-blockers">Calcium Channel Blockers</a></li>
<li><a href="/mesh/dihydropyridines">Dihydropyridines</a></li></ul></td></tr><tr><th>CAS number</th><td>55985-32-5</td></tr><tr><th>Weight</th><td>Average: 479.525<br>Monoisotopic: 479.205635675</td></tr><tr><th>Chemical Formula</th><td>C<sub>26</sub>H<sub>29</sub>N<sub>3</sub>O<sub>6</sub></td></tr><tr><th>InChI Key</th><td>ZBBHBTPTTSWHBA-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-{2-[benzyl(methyl)amino]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Pyridines and Derivatives</td></tr><tr><th>Subclass</th><td>Hydropyridines</td></tr><tr><th>Direct parent</th><td>Dihydropyridinecarboxylic Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>Nitrobenzenes; Dicarboxylic Acids and Derivatives; Nitro Compounds; Nitronic Acids; Tertiary Amines; Carboxylic Acid Esters; Organic Oxoazanium Compounds; Enolates; Enamines; Polyamines; Ethers</td></tr><tr><th>Substituents</th><td>benzene; dicarboxylic acid derivative; nitronic acid; nitro compound; tertiary amine; carboxylic acid ester; organic oxoazanium; polyamine; enolate; ether; carboxylic acid derivative; enamine; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used for the management of patients with chronic stable angina and for the treatment of hypertension.</td></tr><tr><th>Pharmacodynamics</th><td>Nicardipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nicardipine is similar to other peripheral vasodilators. Nicardipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.</td></tr><tr><th>Mechanism of action</th><td>By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.</td></tr><tr><th>Absorption</th><td>While nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>8.3 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>&gt;95%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Nicardipine HCl is metabolized extensively by the liver.</p></td></tr><tr><th>Route of elimination</th><td>Nicardipine has been shown to be rapidly and extensively metabolized by the liver.</td></tr><tr><th>Half life</th><td>8.6 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.4 L/hr&#8729;kg [Following infusion]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Oral LD<sub>50</sub> Rat = 184 mg/kg, Oral LD<sub>50</sub> Mouse = 322 mg/kg</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.932</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9549</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.83</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8581</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.9036</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8253</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7502</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8296</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.5554</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7228</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8948</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7959</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.8558</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.562
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7262
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9604
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9030 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.7332
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7316
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Ekr therapeutics inc</li>
<li>Amneal pharmaceutical</li>
<li>Barr laboratories inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Bioniche pharma usa llc</li>
<li>Exela pharma sciences</li>
<li>Navinta llc</li>
<li>Pharmaforce inc</li>
<li>Sun pharma global inc</li>
<li>Wockhardt ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amneal.com">Amneal Pharmaceuticals</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li>Berk Pharmaceuticals</li>
<li>Chelsea Laboratories Inc.</li>
<li><a href="http://www.ekrtx.com">EKR Therapeutics Inc.</a></li>
<li><a href="http://www.emcure.co.in">Emcure Pharmaceuticals Ltd.</a></li>
<li>Genpharm LP</li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.legacypackaging.com">Legacy Pharmaceuticals Packaging LLC</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.pdl.com">PDL BioPharma Inc.</a></li>
<li><a href="http://www.pharmaforceinc.com">Pharmaforce Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.sunpharma.com">Sun Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>20 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>30 mg</td></tr><tr><td>Capsule, extended release</td><td>Oral</td><td>30 mg</td></tr><tr><td>Capsule, extended release</td><td>Oral</td><td>45 mg</td></tr><tr><td>Capsule, extended release</td><td>Oral</td><td>60 mg</td></tr><tr><td>Injection, solution, concentrate</td><td>Intravenous</td><td>2.5 mg/ml</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nicardipine is initiated, discontinued or dose changed. Dosage adjustments may be required. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Nicardipine increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB01219">Dantrolene</a></td><td>Nicardipine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nicardipine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>The calcium channel blocker, Nicardipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nicardipine therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Nicardipine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Nicardipine may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Nicardipine may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Nicardipine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nicardipine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Co-administration may result in altered plasma concentrations of Nicardipine and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Nicardipine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00444">Teniposide</a></td><td>The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00599">Thiopental</a></td><td>The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nicardipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nicardipine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00906">Tiagabine</a></td><td>The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may alter the concentration of Nicardipine. Monitor for efficacy and adverse/toxic effects of Nicardipine.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Nicardipine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Nicardipine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
</td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Nicardipine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00214">Torasemide</a></td><td>Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Nicardipine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Nicardipine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Nicardipine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor, Nicardipine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Nicardipine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>The strong CYP2C9 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nicardipine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>Nicardipine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.</td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Nicardipine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nicardipine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>Nicardipine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00541">Vincristine</a></td><td>Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00361">Vinorelbine</a></td><td>Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nicardipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole and nicardipine if concomitant therapy is initiated, discontinued or doses are changed.	</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00549">Zafirlukast</a></td><td>Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00425">Zolpidem</a></td><td>Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nicardipine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00909">Zonisamide</a></td><td>Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01198">Zopiclone</a></td><td>Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nicardipine is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>